Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05414409 · ClinicalTrials.gov registry record · Phase 2
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
A Phase 2 study of Obesity and Type 1 Diabetes, sponsored by Heba M. Ismail.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT05414409 is a Phase 2 study of Obesity and Type 1 Diabetes that is actively recruiting participants, run by Heba M. Ismail. The registered enrollment target is 114 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05414409, a Phase 2 study of Obesity and Type 1 Diabetes, is actively recruiting participants, sponsored by Heba M. Ismail.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Conditions Studied
Interventions
- DRUG Metformin
Study Locations (1)
Indiana
- Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2026-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05414409
The ClinicalTrials.gov registry entry for NCT05414409 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower). The listed sponsor is Heba M. Ismail, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Metformin is the first listed.
NCT05414409 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT05414409 about?
NCT05414409 is a clinical study titled "The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action". Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight...
What is the current status of trial NCT05414409?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2022-09-30. Estimated completion is 2026-11-02.
What conditions does trial NCT05414409 study?
This clinical trial studies the following conditions: Obesity, Type 1 Diabetes.
What interventions are being tested in trial NCT05414409?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT05414409?
This trial is sponsored by Heba M. Ismail, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05414409 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.